CN110812354A - Application of bergenin in preparation of medicine for treating severe sepsis of whole body - Google Patents
Application of bergenin in preparation of medicine for treating severe sepsis of whole body Download PDFInfo
- Publication number
- CN110812354A CN110812354A CN201911244949.5A CN201911244949A CN110812354A CN 110812354 A CN110812354 A CN 110812354A CN 201911244949 A CN201911244949 A CN 201911244949A CN 110812354 A CN110812354 A CN 110812354A
- Authority
- CN
- China
- Prior art keywords
- bergenin
- severe sepsis
- tnf
- lps
- caused
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an application of bergenin in preparing a medicine for treating severe sepsis, which belongs to the technical field of biological medicines, and the inventor of the invention finds that the bergenin can inhibit the increase of TNF- α -6 and the reduction of IL-10 caused by severe sepsis in serum, inhibit the increase of TNF- α -6 and the reduction of IL-10 caused by severe sepsis in liver, inhibit the increase of TNF- α -6 and the reduction of IL-10 caused by severe sepsis in lung, and inhibit the increase of TNF- α -6 and the reduction of IL-10 caused by severe sepsis in spleen to improve and treat severe sepsis.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to application of bergenin in preparing a medicine for treating severe sepsis of the whole body.
Background
Sepsis is a serious life-threatening medical condition that manifests itself primarily as a life-threatening multiple organ dysfunction caused by an immune response that is dysregulated by infection. Sepsis is an excessive inflammatory response caused by irritation of the body due to the rapid proliferation of various pathogenic bacteria into the body's blood system and the production of large amounts of toxins.
Severe sepsis is one of sepsis, and compared with general inflammation and sepsis, severe sepsis is extremely serious and the fatality rate of patients is high, and at present, the main difficulty in treating severe sepsis is difficult diagnosis and treatment. Until now, no effective treatment method specially aiming at severe sepsis exists, so that the research and development of new medicaments for treating severe sepsis is a problem which needs to be solved urgently at present.
Bergenin (Bm) is an isocoumarin compound obtained by separating Bergenin monohydrate from bergenia plant of Saxifragaceae; the molecular formula is C14H16O9Molecular weight of 328.27, CAS No.477-90-7, and structural formula as follows:
rhizoma Seu herba Bergeniae has antipyretic, analgesic, antitussive, expectorant, kidney protecting, antidiabetic, HIV resisting, and anticoagulant effects. However, the therapeutic effect of bergenin on severe sepsis and the related mechanism research thereof are not reported yet.
Disclosure of Invention
The invention aims to enrich the medical application of bergenin and provide the application of bergenin in preparing a medicine for treating severe sepsis aiming at the problem of insufficient treatment of severe sepsis in the prior art.
In order to achieve the above purpose, the invention provides the following technical scheme:
the invention provides application of bergenin in preparing a medicine for treating severe sepsis of the whole body.
In addition, the invention provides application of bergenin in preparing a medicine for treating severe liver sepsis.
In addition, the invention provides application of bergenin in preparing a medicine for treating severe sepsis of lungs.
In addition, the invention provides application of bergenin in preparation of a medicine for treating severe spleen sepsis.
Preferably, the use comprises use of bergenin to ameliorate the decrease in cell survival caused by severe sepsis.
Preferably, the use comprises inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in serum by using bergenin, inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in liver by using bergenin, inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in lung by using bergenin, and inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in spleen by using bergenin.
Preferably, the use comprises the use of bergenin to reduce lung damage caused by severe sepsis.
Preferably, the use comprises use of bergenin to inhibit increased phosphorylation of ERK1/2, JNK and p38 caused by severe sepsis.
Preferably, the use comprises use of bergenin to inhibit increased phosphorylation of I κ B and NF- κ B resulting from severe sepsis.
Preferably, the bergenin can be mixed with a pharmaceutically acceptable carrier for preparing a medicament for treating systemic sepsis.
The invention has the beneficial effects that:
1. the invention provides a new application of bergenin and provides a new treatment mode for treating severe sepsis patients.
2. The invention proves that the bergenin can improve and treat severe sepsis by inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in serum, inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in liver by using the bergenin, inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in lung by using the bergenin, and inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in spleen by using the bergenin.
3. The invention proves that bergenin can improve and treat severe sepsis by reducing lung injury caused by severe sepsis and inhibiting the increase of phosphorylation degrees of ERK1/2, JNK and p38 and the increase of phosphorylation degrees of I kappa B and NF-kappa B caused by severe sepsis.
4. The bergenin is derived from bergenia purpurascens extract, has low toxicity and good therapeutic effect, and can reduce antibiotic usage when used for treating sepsis.
Drawings
FIG. 1 Effect of bergenin on cell survival.
FIG. 2 Effect of bergenin on inflammatory cytokine secretion in LPS challenged RAW264.7 cells.
FIG. 3 Effect of bergenin on the secretion of inflammatory cytokines in the serum of LPS challenged C57 mice.
FIG. 4 Effect of bergenin on the secretion of inflammatory cytokines in the liver of LPS challenged C57 mice.
FIG. 5 Effect of bergenin on inflammatory cytokine secretion in the spleen of LPS challenged C57 mice.
FIG. 6 Effect of bergenin on inflammatory cytokine secretion in the lungs of LPS challenged C57 mice.
FIG. 7 Effect of bergenin on lung pathology in LPS infected mice.
(A) Blank group TNF- α (B) LPS group TNF- α (C) bergenia group TNF- α
(D) Blank IL-10 (E) LPS group IL-10 (F) bergenia group IL-10
FIG. 8 effect of bergenin on MAPK and NF-. kappa.B pathway status in LPS-infected C57 mouse lung histones.
(A) Effect of bergenin on p38, ERK and JNK phosphorylation in lung histones of LPS-infected C57 mice. (B) Effect of bergenin on phosphorylation of I κ B and NF- κ B in lung histones of LPS-infected C57 mice.
Detailed Description
In order to clearly illustrate the technical features of the present solution, the present solution is explained below by way of specific embodiments.
Example 1
Effect of bergenin on cell survival
Experimental methods
Grouping experiments: blank control group, LPS group, bergenin group
RAW264.7 cells were seeded into 96-well plates (2X 10)4Cells/well) for 24 hours and added with bergenin at a concentration of 6 μ g/ml, treated for 1 hour, and then exposed to LPS for 18 hours. Subsequently, the 96-well plate was washed twice with PBS, MTT (5mg/ml) was added to the cells, and then incubated for another 4 hours. Adding DMSO for dissolving, and measuring the absorbance at 570 nm; the blank control group was not treated at all, and the LPS group was treated with LPS only and without bergenin.
Results of the experiment
TABLE 1 Effect of bergenin on cell survival
(all data are expressed as mean ± SEM (n ═ 5)##P<0.01 compared to a blank control group;*P<0.05，**P<0.01, compared to the LPS group.
The cell survival rate of RAW264.7 cells treated by bergenin (6 mu g/ml) after LPS infection is shown in figure 1 and table 1, compared with a blank control group, the cell survival rate of an LPS group is reduced to 0.30, the difference is extremely obvious (P is less than 0.01), and the success of molding of the invention is proved; compared with the LPS group, the bergenin group has higher cell survival rate and obvious difference (P is less than 0.01). The bergenin has the functions of protecting cells and promoting cell growth.
Example 2
Anti-inflammatory effect of bergenin on cells
Experimental methods
Experimental grouping and administration treatment As in example 1, each group was provided with 5 multiple wells, and after the administration treatment, the cells were placed at 37 ℃ in 5% CO2Continuously culturing for 72h in an incubator, then blowing and beating the cells uniformly in a 96-well plate, collecting cell suspension, centrifuging (3000r/min, 20min), collecting cell supernatant, and detecting the contents of TNF- α, IL-10 and IL-6 according to the operation steps of an ELISA detection kit.
Results of the experiment
TABLE 2 Effect of bergenin on inflammatory cytokine secretion in LPS challenged RAW264.7 cells
(all data are expressed as mean ± SEM (n ═ 5)##P<0.01 compared to a blank control group;*P<0.05，**P<0.01, compared to the LPS group. )
The contents of TNF- α, IL-6 and IL-10 of RAW264.7 cells treated by bergenin (6 mu g/ml) after LPS infection are shown in figure 2 and table 2, compared with a blank control group, the LPS group has the advantages that TNF- α and IL-6 are increased to 148.03pg/ml and 42.14pg/ml, and IL-10 is reduced to 26.19pg/ml, and the difference is extremely obvious (P < 0.01), so that the modeling success of the invention is proved, compared with the LPS group, the bergenin group has the advantages of TNF- α and IL-6 reduction, and IL-10 increase and obvious difference (P < 0.01), so that the bergenin can play an anti-inflammatory role on the cells.
Example 3
The effects of bergenin on TNF- α, IL-10, IL-6 in mouse serum, liver, spleen, and lung
Experimental mode
Grouping experiments: blank control group, bergenin group, LPS group
Randomly dividing 18 mice into a blank control group, a bergenin group (300 mu g/ml) and an LPS group (10 mg/kg), wherein each group comprises 6 mice, injecting 300 mu g/ml bergenin into the bergenin mice, treating for 1 hour, then performing toxicity attack on the bergenin group and the LPS group, collecting the mouse serum, liver, spleen and lung of each group without any treatment on the blank control group, preparing a tissue homogenate suspension, diluting the tissue homogenate suspension by 10 times, centrifuging at 3600r/min for 10 minutes, collecting the supernatant, and then detecting the levels of TNF- α, IL-10 and IL-6 in the serum, liver, spleen and lung according to an ELISA homogenate detection kit.
Results of the experiment
TABLE 3 Effect of bergenin on the secretion of inflammatory cytokines in the serum of LPS challenged C57 mice
(all data are expressed as mean ± SEM (n ═ 5)##P<0.01 compared to a blank control group;*P<0.05，**P<0.01, compared to the LPS group. )
The contents of TNF- α, IL-6 and IL-10 in the serum of mice treated by bergenin (300 mu g/ml) after LPS infection are shown in figure 3 and table 3, compared with a blank control group, the LPS group has the advantages that TNF- α and IL-6 in the serum of the mice are increased, IL-10 is reduced, and the difference is extremely obvious (P is less than 0.01), thereby proving that the modeling of the invention is successful, compared with the LPS group, the bergenin group has the advantages that TNF- α and IL-6 are reduced, IL-10 is increased, and the difference is obvious (P is less than 0.01), thereby showing that the bergenin has the inhibiting effect on the general inflammation of mice with severe sepsis and infected by LPS.
(2) Effect of bergenin on TNF- α, IL-10, IL-6 content in liver homogenate supernatant
TABLE 4 Effect of bergenin on inflammatory cytokine secretion in the liver of LPS challenged C57 mice
(all data are expressed as mean ± SEM (n ═ 5)##P<0.01 compared to a blank control group;*P<0.05，**P<0.01, compared to the LPS group. )
The contents of TNF- α, IL-6 and IL-10 in liver homogenate supernatant of mice treated by bergenin (300 mu g/ml) after LPS infection are shown in figure 4 and table 4, compared with a blank control group, the liver of the mice is increased in TNF- α and IL-6, and reduced in IL-10, and the difference is extremely obvious (P is less than 0.01), which proves that the model making of the invention is successful, compared with the LPS group, the bergenin group is decreased in TNF- α and IL-6, and increased in IL-10, and the difference is obvious (P is less than 0.01), which shows that the bergenin has an inhibiting effect on the liver inflammation of severe sepsis mice infected by LPS.
(3) Effect of bergenin on TNF- α, IL-10, IL-6 content in spleen homogenate supernatant
TABLE 5 Effect of bergenin on inflammatory cytokine secretion in the spleen of LPS challenged C57 mice
(all data are expressed as mean ± SEM (n ═ 5)##P<0.01 compared to a blank control group;*P<0.05，**P<0.01, compared to the LPS group. )
The contents of TNF- α, IL-6 and IL-10 in spleen homogenate supernatant of mice treated with bergenin (300 mu g/ml) after LPS infection are shown in figure 5 and table 5, compared with a blank control group, the spleen of the mice is increased in TNF- α and IL-6, and the IL-10 is reduced and has extremely obvious difference (P < 0.01) in the LPS group, which proves that the model building of the invention is successful, compared with the LPS group, the bergenin group is decreased in TNF- α and IL-6, and the IL-10 is increased and has obvious difference (P < 0.01), which shows that the bergenin has an inhibiting effect on spleen inflammation of severe sepsis mice infected with LPS.
(4) Effect of bergenin on TNF- α, IL-10, IL-6 content in lung homogenate supernatant
TABLE 6 Effect of bergenin on inflammatory cytokine secretion in the lungs of LPS challenged C57 mice
(all data are expressed as mean ± SEM (n ═ 5)##P<0.01 compared to a blank control group;*P<0.05，**P<0.01, compared to the LPS group. )
The contents of TNF- α, IL-6 and IL-10 in lung homogenate supernatant of mice treated by bergenin (300 mu g/ml) after LPS infection are shown in figure 6 and table 6, compared with a blank control group, the lung of the mice is increased in TNF- α and IL-6, and the IL-10 is reduced, and the difference is extremely obvious (P is less than 0.01), so that the success of model making of the invention is proved, compared with the LPS group, the bergenin group is decreased in TNF- α and IL-6, and the IL-10 is increased, and the difference is obvious (P is less than 0.01), and the bergenin has an inhibiting effect on lung inflammation of severe sepsis mice infected by LPS.
Example 4
Experimental methods
The lungs of each group of mice obtained in example 3 were immunohistochemically prepared into pathological tissue sections.
Results of the experiment
As shown in FIG. 7, the lung injury of mice treated with bergenin (300. mu.g/ml) was slightly less than that of LPS group. The bergenin has protective effect on lung of mice infected with LPS and severe sepsis.
Example 5
Experimental methods
Total protein was extracted from lung tissue of each group of mice obtained in example 3, and the content was measured and detected using Western Blot.
Results of the experiment
The phosphorylation degrees of ERK, JNK and P38 in the lung of the mouse after the mouse is infected by LPS (mouse lung) treated by bergenin (300 mu g/ml) are shown in figure 8-A, compared with a blank control group, the phosphorylation degrees of ERK, JNK and P38 of the LPS group are all increased, and the difference is extremely obvious (P is less than 0.01), so that the molding success of the invention is proved; compared with the LPS group, the phosphorylation degrees of ERK, JNK and P38 in the bergenin group are all reduced, and the difference is obvious (P is less than 0.05). The bergenin is shown to have an inhibiting effect on the lung MAPK pathway of LPS infected severe sepsis mice.
The phosphorylation degrees of mouse lung Ikappa B and P65 of mice treated with bergenin (300 mu g/ml) after LPS infection are shown in figure 8-B, compared with a blank control group, the phosphorylation degree of I kappa B, P65 of an LPS group is increased, and the difference is extremely obvious (P is less than 0.01), so that the modeling success of the invention is proved, and compared with the LPS group, the phosphorylation degree of bergenin group I kappa B, P65 is reduced, and the difference is obvious (P is less than 0.05). The bergenin is proved to have an inhibiting effect on the NF-kB passage of the lung of a mouse infected with LPS and severe sepsis.
In conclusion, the bergenin can improve and treat severe sepsis by inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in serum, inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in liver by using the bergenin, inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in lung by using the bergenin, and inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in spleen by using the bergenin.
Secondly, bergenin can improve and treat severe sepsis by reducing lung injury caused by severe sepsis and inhibiting the increase of phosphorylation degree of ERK1/2, JNK and p38 and the increase of phosphorylation degree of I kappa B and NF-kappa B caused by severe sepsis.
Claims (10)
1. The application of bergenin in preparing medicine for treating severe sepsis of whole body is provided.
2. The application of bergenin in preparing medicine for treating liver severe sepsis is provided.
3. The application of bergenin in preparing medicine for treating severe sepsis of lung is provided.
4. The application of bergenin in preparing medicine for treating spleen severe sepsis is provided.
5. Use according to any one of claims 1 to 4, wherein the use comprises use of bergenin to ameliorate the decrease in cell survival caused by severe sepsis.
6. The use according to any one of claims 1 to 4, wherein the use comprises using bergenin to inhibit the increase in TNF- α -6 and decrease in IL-10 in serum caused by severe sepsis, using bergenin to inhibit the increase in TNF- α -6 and decrease in IL-10 in liver caused by severe sepsis, using bergenin to inhibit the increase in TNF- α -6 and decrease in IL-10 in lung caused by severe sepsis, and using bergenin to inhibit the increase in TNF- α -6 and decrease in IL-10 in spleen caused by severe sepsis.
7. Use according to any one of claims 1-4, wherein the use comprises the use of bergenin for reducing lung damage caused by severe sepsis.
8. Use according to any one of claims 1 to 4, wherein the use comprises the use of bergenin to inhibit increased phosphorylation of ERK1/2, JNK and p38 in severe sepsis.
9. Use according to any one of claims 1 to 4, wherein the use comprises the use of bergenin to inhibit increased phosphorylation of I κ B and NF- κ B from severe sepsis.
10. Use according to any one of claims 1 to 4, wherein bergenin is in admixture with a pharmaceutically acceptable carrier for the manufacture of a medicament for the treatment of systemic sepsis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911244949.5A CN110812354A (en) | 2019-12-06 | 2019-12-06 | Application of bergenin in preparation of medicine for treating severe sepsis of whole body |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911244949.5A CN110812354A (en) | 2019-12-06 | 2019-12-06 | Application of bergenin in preparation of medicine for treating severe sepsis of whole body |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110812354A true CN110812354A (en) | 2020-02-21 |
Family
ID=69545210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911244949.5A Pending CN110812354A (en) | 2019-12-06 | 2019-12-06 | Application of bergenin in preparation of medicine for treating severe sepsis of whole body |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110812354A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011384A (en) * | 2007-02-02 | 2007-08-08 | 四川大学 | Pharmaceutical composition with antiphlogistic, antitussive and apophlegmatic function and its preparing process |
| JP2008169174A (en) * | 2007-01-15 | 2008-07-24 | Yoshihiro Futamura | Bergenin derivative having inflammatory cytokine production-inhibiting action, food preparation, cosmetic, antiinflammatory agent comprising the same |
-
2019
- 2019-12-06 CN CN201911244949.5A patent/CN110812354A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008169174A (en) * | 2007-01-15 | 2008-07-24 | Yoshihiro Futamura | Bergenin derivative having inflammatory cytokine production-inhibiting action, food preparation, cosmetic, antiinflammatory agent comprising the same |
| CN101011384A (en) * | 2007-02-02 | 2007-08-08 | 四川大学 | Pharmaceutical composition with antiphlogistic, antitussive and apophlegmatic function and its preparing process |
Non-Patent Citations (3)
| Title |
|---|
| 任懂平等: "脂多糖诱导小鼠感染模型免疫机制及与人类相关疾病的差异", 《当代医学》 * |
| 沈映冰等: "岩白菜素对脂多糖诱导RAW264.7细胞IL-6、TNF-α及NF-κB表达的影响", 《JOURNAL OF CHINESE MEDICINAL MATERIALS》 * |
| 高明等: "《急诊急救与急诊创伤处置要点》", 31 May 2018, 科学技术文献出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20110132407A (en) | Plant extract compositions for prevention and treatment of influenza | |
| CN110870862B (en) | Application of bergenin in preparing medicine for treating in vivo Klebsiella pneumoniae infection | |
| CN108578420B (en) | Application of luteolin in preparation of medicines for preventing and treating sepsis | |
| CN113384647B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating acute lung injury | |
| CN110812354A (en) | Application of bergenin in preparation of medicine for treating severe sepsis of whole body | |
| CN110859848A (en) | Application of thesin I in preparation of medicine for treating severe sepsis of whole body | |
| JP2024504555A (en) | Use of norharman in the manufacture of drugs for the prevention and treatment of acute pancreatitis | |
| CN113908149A (en) | Application of formononetin in preparation of medicine for preventing and treating acute lung injury | |
| CN1381259A (en) | Medicine for treating diseases of rectum and anus | |
| CN110354215B (en) | Traditional Chinese medicine composition and medicine for treating cough caused by lung yin deficiency with dampness and preparation method of traditional Chinese medicine composition and medicine | |
| CN112076247B (en) | Application of perilla leaf extract in preparation of medicine for treating chronic obstructive pulmonary disease | |
| CN110464755B (en) | A Chinese medicinal tablet for treating acute pyelonephritis | |
| CN114569595B (en) | Application of hericium erinaceus-derived aromatic compound in preparation of anti-inflammatory drugs | |
| CN102397458A (en) | Medicinal composition for treating senile pneumonia and preparation method thereof | |
| CN110898052A (en) | Application of kaempferol in preparation of medicine for treating sepsis | |
| US20200297793A1 (en) | Traditional chinese medicine composition for treating interstitial pulmonary fibrosis and method for making same | |
| CN111000919A (en) | Application of ethanol extract of evodia lepta in preparation of medicine for treating sepsis | |
| CN105031025B (en) | Compound Chinese medicinal preparation for treating porcine mycoplasmal pneumonia and preparation method thereof | |
| CN103961654B (en) | A kind of White staphylococcus sheet and preparation method thereof | |
| CN116139258B (en) | Application of roxburgh rose SOD in preparing medicine for preventing or treating intestinal diseases | |
| CN113577076B (en) | Application of gelsemine in preparation of medicine for treating acute lung injury | |
| CN113209104B (en) | Application of Jak3 inhibitor in preparation of medicine for treating acute respiratory distress syndrome | |
| CN114917285B (en) | Application of polysaccharide compound in medicine for preventing and treating respiratory tract virus infection | |
| CN113908169B (en) | Pharmaceutical composition and application thereof | |
| CN108355106B (en) | Traditional Chinese medicine formula for ventilating lung and abating fever |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200221 |
|
| RJ01 | Rejection of invention patent application after publication |